Chongqing Daxin Pharmaceutical

Company snapshot

Chongqing Claruvis Pharmaceutical is a pharma organization headquartered in CN. Primary therapeutic focus areas include Non-Muscle Invasive Bladder Urothelial Carcinoma, Nasopharyngeal Cancinoma (NPC). NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (1), phase 3 (1).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Chongqing Daxin Pharmaceutical. Not investment advice.

• What is Chongqing Daxin Pharmaceutical?

  Chongqing Claruvis Pharmaceutical is a pharma organization headquartered in CN. Primary therapeutic focus areas include Non-Muscle Invasive Bladder Urothelial Carcinoma, Nasopharyngeal Cancinoma (NPC). NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent re

• Is Chongqing Daxin Pharmaceutical publicly traded?

  Chongqing Daxin Pharmaceutical appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Chongqing Daxin Pharmaceutical develop or market?

  We link 6 drug profile(s) where Chongqing Daxin Pharmaceutical is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/chongqing-claruvis-pharmaceutical-co#company-drugs.

• What are the latest developments for Chongqing Daxin Pharmaceutical?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Chongqing Daxin Pharmaceutical focus on?

  Chongqing Daxin Pharmaceutical focuses on Non-Muscle Invasive Bladder Urothelial Carcinoma, Nasopharyngeal Cancinoma (NPC) based on our analysis of their pipeline programs and drug development activities.